Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Net Cash Flow: 2022-2025

Historic Net Cash Flow for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $22.3 million.

  • Axsome Therapeutics' Net Cash Flow rose 90.48% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year increase of 97.68%. This contributed to the annual value of -$70.8 million for FY2024, which is 138.22% down from last year.
  • Latest data reveals that Axsome Therapeutics reported Net Cash Flow of $22.3 million as of Q3 2025, which was up 956.79% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Net Cash Flow registered a high of $190.6 million during Q2 2023, and its lowest value of -$54.8 million during Q1 2024.
  • Over the past 3 years, Axsome Therapeutics' median Net Cash Flow value was -$12.0 million (recorded in 2024), while the average stood at $11.3 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Net Cash Flow surged by 2,687.71% in 2023, and later crashed by 219.88% in 2024.
  • Axsome Therapeutics' Net Cash Flow (Quarterly) stood at -$26.7 million in 2022, then dropped by 13.84% to -$30.4 million in 2023, then skyrocketed by 60.53% to -$12.0 million in 2024, then skyrocketed by 90.48% to $22.3 million in 2025.
  • Its Net Cash Flow was $22.3 million in Q3 2025, compared to $2.1 million in Q2 2025 and -$14.4 million in Q1 2025.